fluticasone furoate/umeclidinium/vilanterol vs Glycopyrronium (PT001)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Glycopyrronium (PT001)
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
Next expected readout: May 2029 · NCT07525375 (registry estimate)
Reported efficacy
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)
Result source: NCT03358147
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Glycopyrronium (PT001) |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT04651777 | —Not reported |
| Trough FEV1, change | 0.1 vs 0.1vs FF/VINCT029246885 other results
| 0.1 vs 0.1±0 vs placeboNCT033581472 other results
|
| ACQ-5, change | —Trial running · NCT04651777 | -0.9 vs -0.9+0.1 vs placeboNCT033581472 other results
|
| OCS dose reduction | —Trial running · NCT04651777 | —Not reported |
Severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Glycopyrronium (PT001)
- —Not reported
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
- Glycopyrronium (PT001)
- 0.1 vs 0.1±0 vs placeboNCT03358147
2 other results
- 0.1 vs 0.1 NCT03358147
- 0.1 vs 0.1 NCT03358147
ACQ-5, change
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Glycopyrronium (PT001)
- -0.9 vs -0.9+0.1 vs placeboNCT03358147
2 other results
- -0.8 vs -0.9 NCT03358147
- -1.0 vs -0.9 NCT03358147
OCS dose reduction
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Glycopyrronium (PT001)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Glycopyrronium (PT001): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol Rows use multiple source trials | Glycopyrronium (PT001) |
|---|---|---|
| ACQ-7 absolute change · score | -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 uga,b,c,d,e NCT04937387 · Phase 3 · Asthma · phase 3 show 1 more dose-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 | -0.78 vs -0.8 placebo score @ 24wk28.8 μga,b,c,d,e NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more doses-0.73 vs -0.8 placebo score @ 24wk14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 -0.9 vs -0.8 placebo score @ 24wk7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Dropout rate | 7.7%100/31.25/25 mcgf NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | 14.5%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results16.3%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 14.2%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Discontinued due to AEs | 0.7%100/31.25/25 mcgf NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | 1.3%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results3.8%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.9%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Serious AEs | 4.4%100/31.25/25 mcgf NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | 3.8%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results2.9%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.5%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Most frequent reported AEs | 100/31.25/25 mcgf nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination | 28.8 μg upper respiratory tract infection 6% (placebo 8%) nasopharyngitis 4.7% (placebo 3.4%) sinusitis 4.3% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results14.4 μg nasopharyngitis 6.3% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 2.9% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 7.2 μg nasopharyngitis 7.1% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 1.7% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2/3.
- cPopulation context differs: baseline_threshold differs (acq6>=1.5, fev1_pct_predicted<85 versus fev1_pct_predicted<85, fev1_pct_predicted>40).
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 12 weeks versus 24 weeks.
- fPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 3 more results
Glycopyrronium (PT001)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Glycopyrronium (PT001)'s landscape